方盛制药：拟受让“复方醋酸地塞米松乳膏”药品上市许可

Core Viewpoint - Fangsheng Pharmaceutical (603998) announced on October 9 that it signed a technology transfer contract with Yifan Pharmaceutical on September 30, acquiring the marketing authorization for "Compound Dexamethasone Acetate Cream" [1] Group 1 - The acquired drug is indicated for localized pruritus, neurodermatitis, contact dermatitis, seborrheic dermatitis, and chronic eczema [1]